Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | LGMN | Q99538 | 2/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NEK2 | P51955 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12856205 | 0.88 | LGMN (0.51) | MAPTLGMNLMNANEK2HSD17B10 | |
| SCHEMBL12312271 | 0.88 | GAK (0.53) | MAPTLGMNPDK2NEK2HSD17B10 | |
| SCHEMBL7209201 | 0.88 | LGMN (0.51) | MAPTLGMNPDK2NEK2HSD17B10 | |
| SCHEMBL27196623 | 0.88 | LGMN (0.61) | MAPTLGMNPDE3BPDE3APDK2 | |
| SCHEMBL12312312 | 0.87 | LGMN (0.48) | MAPTLGMNPDK2KDM4EGAK | |
| SCHEMBL517585 | 0.85 | LGMN (0.46) | MAPTLGMNPDE3ASMN1; SMN2 | |
| SCHEMBL3220823 | 0.84 | MAPT (0.57) | MAPTPDE3BPDE3APDK2LMNA | |
| SCHEMBL22954530 | 0.84 | MAPT (0.41) | MAPTLGMNPDE3BPDE3APDK2 | |
| SCHEMBL18640051 | 0.83 | MAPT (0.55) | MAPTLGMNPDE3BPDE3APDK2 | |
| SCHEMBL3345453 | 0.82 | NTSR1 (0.43) | MAPTLGMNLMNAHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | MAPT 2130/4885LGMN 4603/4885PDE3B 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.